21620-13-3

Basic information

• Product Name: 8-AMINO-1,3-DIMETHYL-1H-BENZO[G]PTERIDINE-2,4-DIONE
• Synonyms: 8-AMINO-1,3-DIMETHYL-1H-BENZO[G]PTERIDINE-2,4-DIONE;8-AMINO-1,3-DIMETHYLBENZO[G]PTERIDINE-2,4(1H,3H)-DIONE
• CAS NO: 21620-13-3
• Molecular Formula: C12H11N5O2
• Molecular Weight: 257.25
• Mol File: 21620-13-3.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 510.5±60.0 °C(Predicted)
• Appearance: /
• Density: 1.476±0.06 g/cm3(Predicted)
• PKA: 0.82±0.20(Predicted)
• CAS DataBase Reference: 8-AMINO-1,3-DIMETHYL-1H-BENZO[G]PTERIDINE-2,4-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-AMINO-1,3-DIMETHYL-1H-BENZO[G]PTERIDINE-2,4-DIONE(21620-13-3)
• EPA Substance Registry System: 8-AMINO-1,3-DIMETHYL-1H-BENZO[G]PTERIDINE-2,4-DIONE(21620-13-3)

Safety Data

• Hazardous Substances Data: 21620-13-3(Hazardous Substances Data)

Upstream product

• 5417-13-0 1,3-dimethylvioluric acid 
• 108-45-2 m-phenylenediamine 

Relevant articles and documents

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING PLK1 INHIBITOR AS ACTIVE INGREDIENT

The present invention relates to a pharmaceutical composition for preventing, treating or alleviating cancer, containing a PLK1 inhibitor as an active ingredient, and a compound according to the present invention selectively binds to PBD of PLK1, thereby having advantages of high selectivity and binding affinity for PLK1 and low toxicity. Therefore, a PLK inhibitor compound according to the present invention can be effectively used as an anticancer agent by inhibiting the growth of various cancer cells, and can be expected to exhibit synergistic effects with existing developed anticancer agents through co-administration, in addition to individual administration thereof.